Is Buffett Primed To Pounce On a Crash?
In 2024, value investing legend Warren Buffett did the seemingly unthinkable by selling stocks aggressively in a year that saw the S&P 500 climb by about 23 percent.
While the exact figures on Buffett’s selling won’t be known until Berkshire Hathaway releases its Q4 earnings report, the total stood at a staggering $133 billion as of the end of Q3. » Read more about: Is Buffett Primed To Pounce On a Crash? »
Read More
The Magnificent 7 Have a New Trillion Dollar Rival
Berkshire Hathaway (NYSE:BRK.B) is arguably one of the most successful companies in American history. The conglomerate founded by Warren Buffett now owns stakes in both large public companies and several wholly-owned subsidiaries.
Berkshire itself has also been a remarkable investment vehicle for its shareholders, boasting a 30-year total return of over 3,000%.
» Read more about: The Magnificent 7 Have a New Trillion Dollar Rival »
Read More
Is Shopify a Slam Dunk Buy on the Dip?
Recently, an under-the-radar tech company has captured the interest of top-tier investment funds. Hedge funds have quietly been acquiring significant shares that displays a conviction in this company’s potential to redefine its market.
So, what’s the stock is it a buy on the dip?
Key Points
- Shopify’s shift beyond subscriptions to financial services,
» Read more about: Is Shopify a Slam Dunk Buy on the Dip? »
Read More
1 Titan Health Stock Is Way Too Cheap
Merck & Co. (NYSE: MRK) might be best known for its drugs like Keytruda and Gardasil, but those blockbusters haven’t been enough to get shareholders excited as the share price has fallen under water this year, down 6%.
It may well be a pharmaceutical powerhouse but recent price weakness suggests that Merck may be flying under the radar for investors,
» Read more about: 1 Titan Health Stock Is Way Too Cheap »
Read More
1 Low-Cost Schwab ETF That Beat The Market
With around $65.7 billion in net assets, Schwab’s US Dividend Equity ETF (SCHD) is one of the most popular funds among investors seeking dividend income from their portfolios.
In the last year, SCHD has even beaten out the S&P 500 by delivering a 27.1% market price return compared to 25.0% from the S&P.
» Read more about: 1 Low-Cost Schwab ETF That Beat The Market »
Read MoreThe Burst
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Spotlight
Is Jessica Alba’s Stock Set For 50% Pop?
The Honest Company (NASDAQ:HNST) is a lifestyle brand most famously associated with founder Jessica Alba that sells a variety of personal care and beauty products, as well as diapers and other baby care products.
It primarily sells online through its own website and other eCommerce channels, though its brand also has a presence in brick-and-mortar retailers.
» Read more about: Is Jessica Alba’s Stock Set For 50% Pop? »
Read MoreThe Daily
A Once-in-a-Decade Opportunity: 1 Magnificent S&P 500 Dividend Stock Down 36% to Double Up on Right Now
It is a beautiful thing when you find a feel-good stock that offers market-beating potential. A perfect example of this combination today is animal healthcare specialist Zoetis (ZTS 1.93%).
Whether helping our furry friends at home, keeping livestock healthy, or doing its part to battle the bird flu outbreak that has sent egg prices sky high,